
Scanning electron micrograph of methicillin-resistant Staphylococcus aureus (MRSA) bacteria being engulfed by an immune cell known as a neutrophil. Johns Hopkins Medicine researchers have discovered that blocking a specific group of enzymes called caspases boosts the ability of immune cells, including neutrophils, to fight MRSA and other dangerous skin infections — and without the use of antibiotics.
Credit: National Institute of Allergy and Infectious Diseases, National Institutes of Health
Johns Hopkins Medicine study uncovers enzyme inhibitor that boosts immune system to fight MRSA and other dangerous skin infections
In what turned out to be one of the most important accidents of all time, Scottish bacteriologist Alexander Fleming returned to his laboratory after a vacation in 1928 to find a clear zone surrounding a piece of mold that had infiltrated a petri dish full of Staphylococcus aureus (S. aureus), a common skin bacterium he was growing.
That region of no bacterial growth was the unplanned birth of a medical miracle, penicillin, and would lead to the era of antibiotics. Now, in a paper published today in the journal Science Translational Medicine, researchers at Johns Hopkins Medicine have announced another accidentally discovered, potentially game-changing treatment — one that may provide an alternative immune-based solution to the danger of antibiotic-resistant bacterial infections.
And like Fleming’s surprise finding, the bacterium of note is once again S. aureus — but this time, methicillin-resistant Staphylococcus aureus, the life-threatening strain unharmed by methicillin and other antibiotics, and better known by its acronym, MRSA.
The paper’s senior author, Lloyd Miller, M.D., Ph.D., former professor of dermatology, infectious diseases and orthopaedic surgery at the Johns Hopkins University School of Medicine, and now with Janssen Research and Development, says the research team was originally intending to study the mechanisms behind MRSA skin infections in mice with and without the ability to manufacture interleukin-1 beta (IL-1?). This protein, transformed into its active form by enzymes called caspases, enhances protective immunity by helping immune cells called neutrophils, monocytes and macrophages fight bacterial infections.
“We gave the mice a blocker of all caspases [pancaspase inhibitor], a compound known as Q-VD-OPH, thinking it would leave both sets of mice more vulnerable to MRSA infection,” Miller says. “To our surprise, blocking caspases had the opposite effect, resulting in a rapid and remarkable clearing of the MRSA bacteria by keeping the immune cells alive and boosting their protective function.”
Sensing they might have accidentally uncovered a means of fighting bacterial “superbugs,” Miller and his colleagues conducted their latest study to confirm the unexpected finding was not a fluke.
The results were encouraging.
“A single oral dose of Q-VD-OPH decreased the size of MRSA skin lesions and rapidly cleared the bacteria compared with vehicle-treated [given the carrier solution without Q-VD-OPH] and untreated mice,” says study lead author Martin Alphonse, Ph.D., a dermatology postdoctoral fellow at the Johns Hopkins University School of Medicine. “And surprisingly, the treatment worked whether IL-1? was present or not — and without administering any antibiotics.”
The researchers, says Alphonse, found that the pancaspase inhibitor reduces apoptosis — one of three main methods the body uses to remove worn-out or damaged cells — of neutrophils and monocytes, leaving them in plentiful numbers and better able to remove MRSA bacteria.
“It’s like a fire department where older firetrucks are kept operating to help put out blazes, when otherwise, they would have been taken out of service,” says Miller.
The researchers also saw enhanced necroptosis — a second controlled cell death process similar to apoptosis — of macrophages, which are mature monocytes.
“The destruction of macrophages by necroptosis releases large amount of tumor necrosis factor, or TNF, a protein that triggers bacteria-fighting immune cells to swarm into an infected area of skin,” says Alphonse.
Finally, the researchers tested whether Q-VD-OPH in mice could have broader activity against two other dangerous skin bacteria, Streptococcus pyogenes (the cause of multiple diseases, including scarlet fever, necrotizing fasciitis and toxic shock syndrome) and Pseudomonas aeruginosa (often a threat to hospitalized patients on ventilators, with catheters or suffering wounds from surgery or burns). The targeting of the body’s immune system against bacteria via pancaspase inhibition — referred to as “host-directed immunotherapy” — proved just as successful as it had been for MRSA.
“It was an accidental finding by Alexander Fleming that led to the golden age of antibiotics, but now that’s nearing the end because of antibiotic-resistant bacteria,” says Miller. “It seems fitting that another surprise in the lab could be the start of a second golden age, the use of host-directed immunotherapy.”
Original Article: ‘Fortunate Accident’ May Yield Immunity Weapon Against Antibiotic-Resistant Bacteria
More from: Johns Hopkins University School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Host-directed immunotherapy
- Roche's new immunotherapy glofitamab gets FDA priority review for blood cancer subtype
The FDA accepted the company's biologics license application (BLA) and is expected to make a decision on this novel cancer immunotherapy by July 1, 2023. Under priority review, the FDA's goal is ...
- New AI-based biomarker can help predict immunotherapy response for patients with lung cancer
These findings are important because immunotherapy is often the first line of treatment for patients with non-small cell lung cancer, which represents 84% of all lung cancers, according to the ...
- Man given a year to live now cancer-free after immunotherapy trial
Robert Glynn, 51, a welder from Worsley in Greater Manchester, said he “wouldn’t be here” if it were not for the remarkable results of the immunotherapy trial run by the Christie NHS ...
- A Triple Immunotherapy Regimen for Pancreatic Cancer
Immunotherapy, including immune checkpoint inhibitors (ICIs), has changed the landscape of cancer treatment in the last decade. Immunotherapies, treatments targeting a patient’s immune system instead ...
- An Antibody 'Decoy' Could Pave the Way for Better Immunotherapy
Immunotherapy called CAR T cell therapy is a treatment that aims to train immune cells to get better at fighting disease, typically some type of lymphoma. Many of these methods use a patient's own ...
Go deeper with Google Headlines on:
Host-directed immunotherapy
[google_news title=”” keyword=”host-directed immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibiotic-resistant bacterial infections
- Stanford University Discovers New Blood Test Could Identify Infections To Reduce Global Antibiotic Overuse
In developing countries, most antibiotic prescriptions are not only pointless — an estimated 70% to 80% of them are given for viral infections, which the medications don’t treat — they’re also harmful ...
- Old cure revived to help fight against antibiotic-resistant superbugs
The Alfred hospital in Melbourne has begun using the pioneering phage therapy, which dates back to 1917 and involves utilising harmless viruses, to kill germs in cases where traditional antibiotics ...
- The clear and present threat of antibiotic resistance
Viral pathogens may have our attention today, but as it happens, more than half of the estimated 13.7 million infection-related deaths that occurred in 2019 were associated with bacterial pathogens.
- Global Antimicrobial Resistance Diagnostics Market Report 2023: Increasing Incidences of Hospital-Acquired Infections Drives Demand
Unsettlingly, bacteria that are resistant to antibiotics and antifungals might ... Increasing Incidences of Hospital-Acquired Infections Nosocomially acquired illnesses that are not existing ...
- Trends in antibiotic resistance for the priority bacterial pathogens in children and adults
Until recently, trends in drug-resistant infections among children have been ... researchers compared the trends in AR for the priority bacterial pathogens among adults and children along with ...
Go deeper with Google Headlines on:
Antibiotic-resistant bacterial infections
[google_news title=”” keyword=”antibiotic-resistant bacterial infections” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]